Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CRISPR Therapeutics AGLTS:0VRQ -0.34%37 Equity-to-Asset is 0.66 as of Jun. 2026, which is 21% below its 10-year median of 0.84. GuruFocus rates LTS:0VRQ with a GF Score™ of 37/100 and a GF Value™ of $5.00 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, CRISPR Therapeutics AG ranks worse than 52.55% on this metric.
CRISPR Therapeutics AG (LTS:0VRQ) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CRISPR Therapeutics AG Equity-to-Asset Related Terms
CRISPR Therapeutics AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0VRQ vs LGND, DFTX, XENE: Equity-to-Asset Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Equity-to-Asset falls into.
CRISPR Therapeutics AG Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CRISPR Therapeutics AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (LTS:0VRQ) has a Equity-to-Asset of 0.66 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CRISPR Therapeutics AG and its competitors. This is 21% below median its historical median of 0.84. According to the industry distribution chart, CRISPR Therapeutics AG ranks #743 out of 1414 companies in the Biotechnology industry, placing it in the top 52.5%.
Is CRISPR Therapeutics AG's Equity-to-Asset too high?
CRISPR Therapeutics AG's current Equity-to-Asset of 0.66 is 21% below median its 10-year median of 0.84. The Biotechnology industry median Equity-to-Asset is 0.69. CRISPR Therapeutics AG's value of 0.66 is 4.3% below this industry median. Based on the distribution chart, CRISPR Therapeutics AG ranks #743 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CRISPR Therapeutics AG has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Equity-to-Asset compare to LGND and DFTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #743 out of 1414 companies for Equity-to-Asset. This places CRISPR Therapeutics AG in the lower half of its industry. The industry median Equity-to-Asset is 0.69. CRISPR Therapeutics AG's value of 0.66 is 4.3% below this benchmark. While the company's 10-year median is 0.84 vs. the industry median of 0.69, CRISPR Therapeutics AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CRISPR Therapeutics AG's current Equity-to-Asset of 0.66 is 4.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CRISPR Therapeutics AG and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Equity-to-Asset is 0.66, which is 21% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.00, compared to a current price of $57.32 — trading 1046.4% above its estimated fair value. The current Equity-to-Asset is 0.66, which is 21% below median its 10-year median of 0.84 and 4.3% below the Biotechnology industry median of 0.69. CRISPR Therapeutics AG's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Equity-to-Asset is 0.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $57.32 is trading 1046.4% above its estimated GF Value™ of $5.00.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for LTS:0VRQ:
Equity-to-Asset: 0.66 (21% below median its 10-year median of 0.84)
GF Value™: $5.00 vs. price of $57.32 (1046.4% above fair value)
Industry Position: 4.3% below the Biotechnology median (#743 of 1414)
No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
37GF Score
Get the complete analysis for LTS:0VRQ
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
